Given the efficacy of T‐DXd in HER2‐low metastatic breast cancer, the question remains whether patients with HER2‐low disease following neoadjuvant therapy will derive similar benefit from T‐DXd. This evidence concerns the gene ERBB2 and breast carcinoma.